<SEC-DOCUMENT>0001129928-13-000042.txt : 20130910
<SEC-HEADER>0001129928-13-000042.hdr.sgml : 20130910
<ACCEPTANCE-DATETIME>20130909175002
ACCESSION NUMBER:		0001129928-13-000042
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130909
FILED AS OF DATE:		20130910
DATE AS OF CHANGE:		20130909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		131086477

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div><br>
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;September 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release Dated September 9, 2013: Oncolytics Biotech&#174; Inc. Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN&#174; in Squamous Cell Lung Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;September 9, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;&#160;Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="onclogo.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in Squamous Cell Lung Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, September 9, 2013 ---</font> Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC) (NASDAQ:ONCY) today announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles. Of 25 evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumour shrinkage (mean shrinkage was 32.7%). Of the 25 evaluable patients, 10 (40%) had partial responses (PRs), while a further 13 (52%) showed stable disease (SD) and two (8%), had progressive disease (PD), for a disease control rate (complete response (CR) + PR + SD) of 92%. A waterfall graph showing individual patient data will be available on the Company's website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.oncolyticsbiotech.com/presentations</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are thrilled to have demonstrated 92% overall tumour shrinkage in this group of patients,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;Squamous cell carcinoma of the lung is notoriously difficult to treat, and these results support further investigation of REOLYSIN in randomized clinical trials for this indication.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The study enrolled patients with metastatic stage IIIB or stage IV, or recurrent, squamous cell carcinoma of the lung, who were chemotherapy-na&#239;ve for their metastatic or recurrent cancer. The primary objective of the trial is to evaluate the patients&#8217; tumour response. The secondary objectives are to assess progression-free survival and overall survival for the treatment regimen in the study population; to determine the proportion of patients receiving the above treatment who were alive and free of disease progression at six months; and to assess the safety and tolerability of the treatment regimen in the study population. Final progression-free survival and safety data for the study will be reported later in 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Lung Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The American Cancer Society&#160;estimates that in 2013, approximately 228,190 new cases of lung cancer will be diagnosed. Between 85% and 90% of all lung cancers are classified as non-small cell lung cancer (NSCLC); squamous cell carcinomas account for 25-30% of all lung cancers. Lung cancer is by far the leading cause of cancer death among both men and women. There will be an estimated 159,480 deaths from lung cancer in&#160;the United States&#160;in 2013, accounting for around 27% of all cancer deaths. Lung cancer is the leading cause of cancer death, with more people dying each year of lung cancer than from colon, breast, and prostate cancers combined. For more information about SCC lung cancer, please go to&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cancer.org</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements, within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#8217;s expectations related to the U.S. Phase II squamous cell carcinoma lung cancer trial, future trials in this indication, and the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research, development and manufacturing of pharmaceuticals, changes in technology, general changes to the economic environment and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta&#160;&#160;T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@tmxequicom.com</font></font></div>
</td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dian Griesel, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Susan Forman</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">396 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">sforman@dgicomm.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
MCQ:R%M86^A<=%T$791>)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW
M&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=
M1QUP'9D=PQWL'A8>0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P
M(1PA2"%U(:$ASB'[(B<B52*"(J\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE
M"24X)6@EER7')?<F)R97)H<FMR;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX
M*6LIG2G0*@(J-2IH*ILJSRL"*S8K:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LM
MX2X6+DPN@BZW+NXO)"]:+Y$OQR_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;
M,M0S#3-&,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPW
MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HKA_B'\2/`_PH\+:IXX^(WBK0/!?A'18&N=4\0^)=5L]'TNSC
M7[JO=WLT,;W$[$0VEK%YES=W#QV]O#)+(JG\"/VE_P#@X"^%_A2YO_#G[,WP
MZO/B?J%N9;=/'GC>:Z\+>"S.&"BYTOP_%'_PE7B&SSM`%Z_A%YMP>T>=$#/X
M6;\29/D5/VF9XRE0;CS0HJ7/B*D=-8TE9Z7UU_,UI4:E:7+3BY6W?1']%]%?
MP^ZK_P`%._\`@J7^TKJMSI_PSU_QE"D[L/\`A%O@!\+4G:U$I!2*+4K#1_$?
MBZ*)0T:+)/KSW&X;?,>1Z?%X`_X+>:^HU(7'[>48G`<*_C_XE^'R%;)'_$NE
M\2:68?I]DB8?Q*,KGY!^)6&J^]E_#V?X^E_S^I83EAK:UM97OKVU5O3H^I27
MQ5:2[>]?M^5_N^X_M_HK^'.Z^(?_``6E^!*G5M9U#]L_3K*S'FSZCXMTCQG\
M0M"AB3.YKJ?Q)I_BC1VB`1FD-S*2%)9E"Q$CW#X+_P#!?']J;P%?6^E?'#P3
MX+^,&C6\GDZC-'IY^'7CA6#+',1>Z5!/X:<PXD86DOA.*:5T,,EVB%YDJAXG
M90JL:69Y?FN4.6]3%X9NE&UMW&U26ZNZ=*:5_>MI=_4*DOX=2E.V_O6MMZI]
M?N/['**_.C]DS_@J#^RO^UV]GH'A#Q3+X)^)-PBY^&/Q`^R:)XCN[@(6F3P[
M=+<SZ+XK1"DC"/1-0GU2.V47%]I=B"R+^B]??8#,<%F>'ABL!B:6*P\_AJT9
M<T7^3^](Y)PE3DX33C);IA111780%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%?$W[;7[<GPF_8C^&8\9^/9O
M[9\5:VEW:_#[X<Z7=0QZ_P",M7@1`^QG60:9H&G&:&;6]?N(9+>QB:.WMXK[
M5KK3],O/;?VA_CSX'_9H^$'C;XT?$6[^S>%_!6CS7\L$+QC4-8U.1DMM%\.Z
M3%(52;5=>U.>VTVQ1F6))IQ-</%:Q331_P`57@_PS^T/_P`%?OVS+^^U74)[
M&#4)EU#Q'K)2XNO"_P`&_A597VVRTC2H'>-6GCAF.G:/8;H+CQ+XBN;C6=3>
M,SZWJ4/PW%_%%?*5A<LRFC]<SW,Y^RPE"/O>P3Y;8BK&VRYO<BW%2M)\RL=>
M$H1K2G.II2I1YY^>NBW5KOK9^A)K'B#]N3_@K]\<O[.L8;S7-/TV[-S:Z#97
M%SHGP;^#VAW4\D$=UJ%PYFM8+GR&D1]2NAJ?BWQ"\,\%BMT%AL(/Z!_V3?\`
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M;6L**JJH6.)<`=3VZ"BBOT"G"-.*A",(16T814(KTBM$<(5\K?'G]BG]F+]I
M?3[JT^,'PA\(>)=0N$D2/Q5;:<FA^-;%GSB:R\7:(;#7HVC<^:()KZ:RF<!;
MNUN8=T3?5-%9XC"X?%P=+$T*.(IO>G6I4ZL7L]IQE;;I;S*4I1^%M>A_'G^V
MQ_P1'^*OP(BOOBK^RUK.O_%?P/H[G5KCPBZB+XL^$(K63[6+_2'TE;6'QC;Z
M>88Y_/TFWT_Q)`(T:#1=0%JUV/6?^":__!9G7/#.IZ'\!?VQM<GU3P]/<6^@
M^$OC1K#,-9\,7:SBU@TCXF2R+YVJ:.96%JGBV=?[5T615/B-KRQ%UJ^E?U9U
M_.;_`,%=O^"6.D^.]#\2?M2?L[>'H['XCZ3;WOB#XK>`=%M&6W\?Z7;0M-J/
MB[0-/MQY</C/355KS5[&WB8>++);RYC@F\3`_P!N?F&<<,8WAFN\_P"$)SIJ
MG=X_)K.>&Q5#3G=.G=*\%=VMI?38]"CB(XA1P^*]Y.RA5O:<'=7MH][1O?LK
MG]%%G>6]_;PW=K+#<6US#%<6UQ;RK/;W%O.N^">"9/W<L4T166.2,M')&ZNC
M,C!C:K^8O_@B+_P4,O=1FL?V,OC%K4E[>16D\GP)\2ZM=%[B6TTZVDN+WX97
MMY.3).]E903:AX->9G=+&VO]`1UBM-`LJ_ITK[KA[/L)Q%EE',L+[JG>G7HM
MWEA\1!+VE&3LKN+:M*RYK['%6I2HU)0ETUB_YH/X9>5UZA1117N&04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%4M1U"UT
MNRN]0O9DM[2QM;F\NIY#A(;:TA>>>9SCA(XD9W/8#N>*&[)OMJ!_)1_P7N_:
MGO?&WQ;\)?LI>%[^:7PY\,(-/\6^.[6TD<KJOQ#\36(DT'2YXXR?M`\.>$]0
MMKBW5-V;[Q9<0E!/IL;)^XG_``3"_8YT_P#9!_9F\.:)J>G0Q?%;XA6VG^./
MBOJ+Q1_:TUO4+19M-\)^;R_V'P7I\XTB.'>T#ZK_`&QJ,(5-1"K_`"_?L7Z+
M=_MR?\%3]%\9^*H#J.CZ_P#%WQC\=_$T%WNN+>'0_"][J?BO0]'N$<.K:;]N
MA\,>&%MG`C2QECMEV(I$G]T-?E7!-&.?YQG?%^)]]SQ=3`97?_ESAJ+?-4C%
M_!4=XJ,E=KWM>WH8J7LJ5+#1O%J//55[W<K./W6EU>^R"BBBOU4\\****`"B
MBB@`IK*'!5@""""&`((/4$'J#QD=\4ZB@#^(_P#X*M_LPZG^Q+^U[H'Q>^$/
MVCPIX0^)&KK\4_AU?:1"+.#P?\0_#^JVNI>)M!TU8<1VT6G:Q]@\1Z5:C;:0
MZ9K::1#`UIIL\:_UL?LB?M`:3^U!^SM\+?C?I:06\OC/PU:S:]IMNY:+1_%N
MER2Z/XNT=-Y:58M/\1V&I0VC2_/<:>+2\`V7",WQ+_P6M^"5I\7/V&O&OB&&
MT6?Q#\%M8T7XGZ+,L8:X2RLYQH'BR`2A#(EH?"VN:GJ5PB.BM=:183,<V\>/
MB_\`X-X/B_/JOPR^//P0O[LR+X)\5^&_B%X>BD<DQV'C?3;S1==M(.HCM[*^
M\(Z?>2*#L,^N22`>9)(@_*,KI+AOCS$Y13M3RSB'#O&X>A'2G3Q4'[1."3?_
M`"\I5Z7V;I*7D=]1>WPD:TOXM&U+FWNDDKVZ7T^X_I"HHKF/%7C'PEX*LH-2
M\8^)_#WA33KBX%I!J'B36]-T&RENV1I$M8KK5+FV@DN9$CDD2!7,C)'(X&$-
M?JLI1A%RG)1BMY2=DM;:MZ'`=/17'>%OB#X&\<"]_P"$,\9^$O%ITXQ#4/\`
MA&?$>CZ_]A,XD,`O/[*O+L6IF$4AA\\QF4(Y484X[&E3JPJQ4Z4XU(/:4)*2
M??5=5V#5;H**Y+Q9XX\&>![>SNO&?BSPSX2M;Z:2"RN?$^OZ7H%O=SQ1B66"
MVGU6YMHYYDB_>M%$7=8U+L%0%AI^'_$>@^*]+@UOPUK6D>(=&NS*+35M"U*S
MU?3+GR9I()A;W^GS7%I,89XI(91%,_ERQO&V'4J!5(.3@I1<XI.4$TY*^UUO
M;SL!M44458!17+>*O&G@_P`$V/\`:?C+Q3X=\*Z<IYOO$>MZ;H=IGT^T:G<V
MT))P>/,SQQWKQ#_AL;]D[[7]C_X:2^!@N=VSRO\`A:O@G?YG_/,#^U\;L]LB
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M`R)/):1ZM>6CW"0O(B3-"KK$SHKE689Z+1]8TS7].M-8T74=/U?2=0@CNM/U
M32KVWU'3K^VE!,=Q9WMH\MM<P.N"DL,LB,<@'CG.-6$I2@IPE4A;GC&2;C?:
MZW5_-`:=%%%:`%%>3:M\>/@KX>U2^T/Q%\7/ACH&M:9/]FU#2-9\>^%M,U2Q
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MLY9K<3121&:)602(Z%@RFIE7I1@JDJE.-)KXY227E9O3\;AJ]$KL[NBO(O\`
MA?\`\"_^BS_";_PX_@__`.7%'_"__@7_`-%G^$W_`(<?P?\`_+BLOKN#?_,3
M0_\`!D/\_/\`/LQV?9_<>NT5Y%_PO_X%?]%G^$_X?$;P=_7617J=G>6VH6T%
M[93P75G=0PW-I=6TJ3V]S;SQK-!<031DQS031.DD4L;/'(C!D9E(-:TJ]&M?
MV56G4Y;<W))2M?:]GI<+-;IKY%JBL;7_`!#H?A72;S7O$FL:7H&B:=$)M0UC
M6]0M-*TNQB:2.%9;S4+Z6"TM8FFEBB$D\T:&22.,$NZ@X?@_XC_#_P"("W[>
M!O'/A#QFNE-;KJ;>%/$FC>(1IYNUE:U%\='O;P6IN5@G:W\_R_/6&0Q[A&^'
M*K3C4A2=2"J34G&FY)3DHVNXQW=KZZ=4+7>VAVM%%%:`%%8FO>)/#_A>QEU3
MQ'KFCZ!IL*LTNH:WJ=EI-C$%`),EW?SP0(`,DEG``')%>!S_`+8G[)]K=M97
M'[27P.BN4?RVB;XI^"PZ2#JCC^U\*PZX)R?;'//6Q>&P[2KXBA1<KV56M3IM
MV:O93DF[73=MM+[C49/:+?R\[=OZ_+Z7HKA_!_Q+^'OQ`@:Y\#^.O!_C&!55
MVF\+>)=&U^-5=2Z[VTJ\N@GRC/S8..O.:[BM*56G6@ITIPJ0>TJ<E.+^:T%J
MMT%%&:\*\:_M-?L\?#2\?3_B!\;_`(4>#K^/?YVG^(?'WA?2[^,I@L'L;G48
MKM6`/"-"';LO:HKXFCAX\]>K2I0M=SJU:=**U2WG*.]^E]M;#LWLG]Q[K17R
MII?[</['FM3K;:9^TU\#+J=F"+&OQ*\)QLSE@JHOG:I'N8L0!MSCN1QGZ,\.
M^*_#/BVQ34_"WB'0_$>G2*K1W^@ZOI^LV3ALD%+K3KBX@8'!Y#X/;-10QN$Q
M+:H8G#UG&UU2KTJK7->UU"3:O9VOO9V\G*$H_%%KU3\O\[&_111742%?.G[7
M.M77AS]E3]I?Q#9,4O-!_9^^,FLVCJQ1UN--^''B*\@*,I5E(FA7Y@<JVT@U
M]%U\\_M9Z#=^*?V6OVD/#%C&\E[XC^`GQ@T*TCC4M(]SJOP[\06-NB*.2QEG
M`51RSD+CFN+,?:/`XM4OXCPN)Y-]_85-K>=BZ7\2G_CA_P"E(_F`_P"#>70+
M6^_:C^,/B&50UUHGP,NM/M&."8QKWCGPBUQ)'D':^S2$BWCD)*Z\ARI_L%K^
M//\`X-ZO$EKI_P"U3\6?#<SJEQXA^!M_>V>XJ/-E\/\`C?P>98$R03(8-5DG
MV@_ZNWE<\(2/[#*^)\,'3?"F']G_`-!>-YO7V\[7\_TM<ZLP_P!XEOLM[[67
M?\?0****_0SB"BBB@`HHHH`****`/!/VHO#EOXO_`&;/C]X6NH_-@\0?!7XI
M:1(FSS&QJ'@?6;=7B4Y_?QR2+)`P!9)51DPP#+_+'_P;W:Y-:?M;?%+P\&S:
MZ[\`M;NY8R[*&N-$\>>`C;2A1PS1QZE=*&;E5E<#AVK^I/\`:N\3VW@O]F']
MH;Q9=R".'P_\$OBEJG+;#)-:>!]::WMU;(Q-<W`BMX.03/+$!R0*_ER_X-[/
M#\UY^U=\6/$VUA:>'_@-JFGRRB/<JW7B#QWX(:UBWXW(TD.CWCJ`PWK#(3G9
MD?F/%.O''`ZI6]M[;%>UV_A<M7V3^7[S^D=^%O\`4\7?;DBOGI_P#^Q&OY\?
M^#B$X_9I^".!U^.A'.?^A!\6_AZ]O_K_`-!U?SW_`/!Q'_R;3\$/^RZ'VX_X
M0'Q;WKWN/7;A+.GVPJ\O^7]$PPG^\T?^OB/Y^_@'XF_::_8HL/A)^VC\,&D3
MP'XYU7Q%X5NI@+JZ\*ZY-X;U:YMM;^'7Q!LHU1(6U6PM(M:T6X:16"R?:])N
MXM4TB\6V_M4_8R_;/^%'[:WPLM?B%\/+Q-/UFP6VLO'G@*_NHY/$/@?Q`\;/
M)87\86(W>F7/ER3:+K<,*6FK6BLP6WO(+VQM/S'_`.".WPI^'_[0?_!,[Q1\
M(_BGX?M/%/@K6_BO\1M%U33;I2DD?F6OA?4K/4;"Y7][IVK:9>SQW^EZC9F&
MYL+V"WNH&$J;V_(?XX_`K]IS_@CG^TGHOQ6^%FKZCK'PQU74I[7PCXRGMII?
M#GC+PW,\EU??#/XH6%JT5O#J\=K%ND53;K>O:P^)_#,UIJ=HT&C_`)_D=;,^
M#LNRO.*,:N-X9S+"8;$9EATW*MEV)J4XPGB*2L[J;BG**Y5-JS:Y=>ZLHXJ=
M2$K0Q4)\B<I6BZ:LE'LW'5:VL?I;_P`'&5N[_"_]F6Z$:E(?'_CV!Y"061KG
MPYHLD:A3@L'^QLS*O4QJ">:^X/\`@B8<_P#!.OX/'C_D8_BN!CIQ\3O%G?\`
M'GBOR-_X*L?M9?#7]MO]A_\`9U^,WP\F-GJ.@_&:?PYX_P#!EU<)-K'@3Q1J
M_@'6=0.E:DBK%]HT^\;1)Y]`UP116NJV,;R)';WL%_I]C^N7_!$S_E'7\'L=
M_$GQ9QQ_U4[Q9_D^]>OD^*HXWQ*S#%X:I&MA\3P]0KT*D7>,J526`Y9+JF[-
M--::Z[F56,H8)1DK2C7Y6O2.OYGZQU_/)_P5:_X*S^(_@!XEU']G#]G*:QM_
MBC8V<7_"Q/B'<P0:G%X&?5+)+NS\/^&K&=9+.Y\4_89[:\U#4]0@N;#1DNK:
MVAM;K53<IIO]#=?Y\_[:.C:QX`_X*$_'C_A9UM<RI!^T;KWBO4X[N.25M4\'
MZ[XP?Q9HUW#$Z@SV&I^$-4LWM((\0&WD6TCV*&">KXD9SC\JR?#4\#5>%>8X
MM8.OC(KW\/1=.4Y.E+_EW5GR\L*FO+9M)LRP5*%6J_:*\8P<N7O:VA^W_P"S
M#_P1T\3?M":)HWQU_;^^+GQ2\6^,/%]C9^(+3X>1^);MM0TO3-307MK;>+/$
M>L?VG?VU_+'*'NO#V@PZ;%H^Y+-K][B&6*W_`$$G_P""+7_!/*;2_P"S5^#6
MIV[[`G]J0?$7X@+JF1T<SR>(Y(&89/RO;-&2>4QQ7Z>Z#K>D^(M&TO7]!O[/
M5-"UK3K'5=&U33YX[BPU'3-1MTN;&]LYXB8I;6ZMY(YK>2-BLD4B./O5L9KV
ML#P=P_AJ$(3P&'QU5I3K8S'1^M8K$5&O>JU*M64VW+HEHO,REB*SDW&<J:;T
MA!N,8^22V/RZ_9G_`."2?[,O[+/Q;?XO^`-7^)^JZO:P/%X>T7Q+XM2;0=`F
MF5HI[M;;1]/T:;6YC`[P6\7B";4[*U5S-':F[2WN(/U%HS17N8#+L%EE%X?`
M8:EA:#DY^RHQY(*3W:2[F4YRG)RD^:3M=]7;T/PG_P""O?\`P4Q\2?LI6^B?
M`WX(S6=M\9O&7A__`(2'6O%MQ#%?K\._"5[=SZ?93:=8W$<MG<^*=;FL]0>Q
M.HQR6^CZ?:?VA)9W,]]IY3Y-_8B_X)13?M?^`_#_`.U'^VU\4_B?XUO?B1`?
M$OA7P@OB:[&HW/AB^D=]-UGQ-XEU-=0U"./6XE-_I>CZ`--2RTB>QD>_,L[6
MEK\&?\%RO#'B+1/V^?%NM:Q!.ND>,O`'PXUKPG<.K^1-I-AX>A\,7T5NY&S]
MQXAT35R\2L2AN$9@/.0M_5[^P/XPT/QQ^Q=^S)KWAV:";35^"?PZT%Q;NC);
MZMX4\.6/A;Q!8N(P%6>QUS1]1L[E,!EGAE!`Q7Y;E\'Q/QOGN$SN<J^"RA2A
M@<M<JD<)-1J4X>WK4HS@JM5*2;E).^R25ST:D5A\'0J4G:I62E*HOB5U=)/I
M;7U\GO\`.$G_``1@_P"">$E@+#_A25\A"&/[<GQ%^(8O^A7>)CXH,8<9SE8`
M#W7IC\I/VYO^"7?B3]A_P;J?[4_[$OQ6^*'AK3_`CV^I>-?"W_"27,>OZ)HL
MES%`->T37])73Y=6TC2[B>$:QH^N6]T\.E//J,M]>6]I=6LG]5.1TR,U\G?M
MV:GHND_L8_M27GB"6UBTL_`/XJ6<ANF41R7>H^"]6T_3+90S*LEQ=:K=65M:
MQY!>YFB4?,1GZ[.^%,BJ9;C*E'`8?`8BAA<16P^+P,%A*^'JTZ?/&<:E!TF]
M8)>\WULUUYZ&)K*K!2G*<92C%QFW*+NTM4^W0_-G_@D7_P`%-_$O[5[:O\"O
MC>;&7XQ^%/#A\0Z'XOM(8K"+XB>&M.N+6PU'^T+"!([.T\5Z3+=VMS=_V;'%
M9ZKIT[ZA%9VLEC?;_P!V*_AQ_P""'^DZQJ7_``4'^'=YIB3-9:%X*^)VJ>(7
MC4E(](F\'W^BPFX(&%A?7M6T6$$G!G>%0"S+C^XZN/PXS?&YQP[&MCZGMJV&
MQ53"*NU[]:G3ITIQJ5']JHW4<9S^TXW*Q]&%&ORT]$X1E;M>^GW+R]#^2?\`
MX.*?^2W?L[_]DK\2?^I:?\]_Z5^]?_!,C_DP?]EK_LE6D?\`I7?U^"?_``<4
MY_X7=^SQ_P!DL\2?^I:?RK]Z_P#@F0<?L#_LM<@?\6JTCK_U]7]>1D#_`.-C
M<6_]@D?_`'2+K/\`V&A_U\?_`*2OZ_X-C[NHHH!STY^E?JIYY^,__!3W_@EQ
MX9_:[T.Z^*GPJM-/\-?M&Z%I["*XQ%9:1\4=/LHQY'A[Q/)M\JVUNWA40>'?
M$K_/`_D:?K#S:0L4VF?DA_P36_X*6>-?V//&;?LH_M71:[I_PSTW7KGPW97O
MB2"[3Q%\#_$*W<EM/87\$X>YD\#_`&MR+VSC$DF@.\^K:6'TMY[63^P>OQ*_
MX*\?\$\OA_\`'SX3>./VC/#,=EX2^-'PD\$:[XNU+6H+=8K'X@^$?!VDW&L:
MAX?\211+NFU>UTVPG'AO6CNN(&C31KWSM,FA^P_G7$W#V*P6)_UHX:?L,UPU
MZN.PW-:AF6'BDZD94TN66):NE)_'?75*_=AZRE'V%76.GLWU@V]?6^F[5K?=
M]Y?M7?ML?!G]DGX/)\7/&^MV>KV^NV@_X5WX<T&_M;O5?B-JMQ;+<Z?:^'7C
M:2!],DBFM[J_U]BVF:=I\\5R\TLMQ96MW_++\*?A3^T[_P`%H?VFM5^)/Q)U
M6^\,?"/PU?Q6?B#7[2*4^%OAYX8$PNK3X>_#FSNE:WU'Q3?6I26>:4,Z_:!X
MB\1-(&L;"^^6OV+?@CXZ_;^^/WPI^`7C3XF^(8/!?@7PIJLT=SJ%]<:K<^%/
MAOX>O&U;4?#O@RTNWDM;*ZU&_P!3BM+(.AM;(W1OI(9K73+>Q7^[/X._!SX=
M?`3X>^'OA;\*O#5CX5\%>&+-;33-+LD^=W.7NM1U&Z;,^I:MJ5PTEYJ>J7CR
MWE_>32W%S*[L37BY?+'>(]6&+QJ>!X:P-:,?[/A6A4JX_'4X4YRAB90:3HP<
M[.$DE*]T^AI44<#>G%<U=QE&4WHHI\MK+WNSO[RU[E/X'_!#X;_L[?#?P[\*
M/A1X=M/#7@WPU9I;VEI`BM=7UV0/MFLZQ>X$VJ:UJD@%QJ6I71>>YGR25C$<
M:?,G[4__``3?_9E_;%\9Z#\0/C7I'BN^\3>&_#,?A+3KKP[XLO\`P_;_`-B0
MZIJ.L0PW%K`DT$TT=_JVH2I<!$E*7'E2&1(H5C^]J*_4*^68#%82.`Q&$H5<
M''V?)AITTZ,?9?!:']V_?4\^$Y0DIP;C);-'\[O[8'_!'/\`8N^#7[+WQV^*
MG@;1?B%9^,/`'PT\2^*_#L]_X\O=2LHM5T:Q>[M&N;*XM/*N86>,1S1,5+PL
MZ*Z%MU?DU_P2%_8P^"O[9WQ.^+?AGXV6GB.]T?P7X%TC7=&A\.Z[-H,HU+4=
M?33Y);FXMX999HTME94A#1KF1F))"[?ZMO\`@HG_`,F*_M5_]D0\=_\`IEG^
MO3_.*_GZ_P"#=7/_``NW]H<#`_XM?X8_'_BK#[C./_KU^39[D>44>.N&,#2R
M_"TL)B:-=U\/3I*%*KIB6W*":3U^Y]SU*%:L\%B).I)RC.*@V[\NBO9:*[NO
M2WF?J(O_``0J_8"4_P#(N?$[&1N4_$G5`&`(.UL6P8`XYVE6]"*_7?PYX?TO
MPIH6C>&M"MDL=$\/Z5I^B:/8Q;C'9:7I=I#8V%I&SN[LEO:P10H78MM09)/-
M;=%?JN!R;*LLE4GE^`PV#E5BHU'0IJ#G%;*5M[:V[-MGFSJU*EO:3E.VUW>U
M[?Y(_,W_`(+#?\HX/VD.W^@_#/\`'_B\GP[X_P#K?_KK\F/^#<9BVO?M:\#(
MTOX*GZ_Z5\3AZ<=?2OUG_P""PW_*.#]I#/\`SX_#/MT_XO+\.O\`/;^A_);_
M`(-Q,_V]^UM_V"_@K_Z5_$WM_P#7_E7Y[G'_`"=#AW_L5S>_][&;?=M^IVT/
M]QQ'_7V'_MA_4W7XD_\`!5G_`(*AS_L>IIWP<^#UMI6K_'7Q-H@UR[U75(UU
M#1_AMX=O3-#I^IW6G`[-2\2:K-:W,FCZ7=$6=I:VXU;4X;N&?3[#4/VVK^$3
M_@LGX:\5^'_^"@_QKO\`Q/#=K:^+(/`WB/PG>W"R""_\,'P/X?T.V:P:0`-:
MV&IZ+JFCE8U5$NM/N$PS[G?V/$7.<?DN0JKE_-"MBL53PDL1'1X>G.G4G.I&
M6\*C5/EA-)\MVTF[(SP-&%:ORU-8J$I6=]6K::-=S]&_V2/^"9OQ<_;V\,Z+
M^TY^W1\<?BEJN@>-8_[;\$>"8=9;^WM4\/7,C266MW=SJ<-YI'@_0]5C!N=%
MT30-$2:;2I;2_%QI\-Q#`WZE6W_!%G_@GE;Z9_9S_!O5+N39L.J7?Q%^(+ZI
MR!ND6>/Q)#`DC,-WR6RHI)"QA>*^T?V5/$_ACQC^S5\!_$/@RZLKKPU?_"+X
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M_@N[^U5^T5\,O$/P\^"7P]U+Q-X`^%?C#P5/XC\1>,_#TEUI=UXXUV34M8TV
M^\%CQ%9-'/9Z?H6FV-EJ.IZ597%I-J1UV#^T/-T];=)>7_X)D?\`!/C_`()[
M_'SX,>&?B#\1_&<7QH^+^MQ75YXR\"7OCVY\-MX(OWO[F)-&E\+Z/J&E>(;M
MFMD@F;6]2O+JQU8S_;-+$5LX#?T?_%KX-_#'XZ^#[WP%\6O!?A_QWX1U`$SZ
M/X@L(KV&.<*5BO;&8[;K3=1MLE[74M.GM;^U<;K>YC8DU^'GQ8_X-^O@OK.O
M7'B'X%_&?QW\('DD:>#0M2L(/&^G:=(SE]FE:D-3\/\`B&WMTR-D=]J>J7(P
M#]KQD5^=9QPUF\.(*N>1PF&XFPE6+A2RS'5U1>`C-1O]6A55:A6Y;)RYZ5Y+
MELJ;OS=5*M3]BJ3E.AROXH7ESWM\2TVMW>[VZ_7?BG_@B[_P3U\36#6EK\']
M3\*3E75-2\+^/_'%M?1,P(#JNJZ[J]C(5RQ5+JRN(B<%XWVC&+^S%_P2`^"7
M[+/QLMOC#X)^*'QAU:WTNWF.B^"-6\106&C1ZG-F)+[7+GPU!HDGB>UM;=C'
M:Z3JMNU@9=D]]'?F&!(_SDU7_@F-_P`%4O@'9/JW[/7[8>I>-K?3%-Q:>&8?
MB!XR\*W=W'#E_L\&@>++C5O!]S)(%!^QWVKP6DN2LA;Y$D\R_9S_`."U_P"T
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M!_=."",@@@\@CD<\C\QS7\GG_!?;]E"]\.^//!W[6_A;3G;1?&]O8>`OB=+:
MQMBP\7:';N/"7B*\:(%PFO\`AVW30O.9T%O=>%],B+F748Z_7C_@E!^VA8_M
M9_LUZ-9>(-5BF^,7PCL]+\%?$BSGF5K[5(;2U-OX8\<>6S>:]OXITVS+7LY1
M5'B&RUM?+BA,`;\JX-K1X>SS.^$<1[D98J>892^E:A6^*C"3MSU+*#A&]W:2
MT:U]#$Q]M2I8F+YGRJ%9V^&UE!OKK>6MO2Y^IE%&:*_53SPHHHH`****`"BB
MH9YXK:)YIY$BAB1Y9997$<<44:&22621B%1(T4L[,0``22`#1>WY@?CQ_P`%
MP?CE9_"O]B7Q!X)MKQ(/$_QR\1:)X`TFW279<_V)9WD'B?QA>^6I#/9#1]'7
M0;OHC3>(K.W<@3\_+_\`P;S_``=N-"^#OQL^-^I6C12?$7QGHG@GP_+-%M>7
M1?A_I]Y?:C>VY))>"^UKQ;+I\Q)*F;P^8L?N2S?D_P#\%)_VD/$'_!0G]L[0
M?AS\&XYO$O@_POK-M\'_`(/6%DS2VOBG7=7U:WM?$'C&!AN2.U\0:N8(K>^;
MRUC\*>']-U&Y\L-=1)_87^R_\"M"_9I^`OPQ^!_AUEGLO`7ABQTN\U!(_*&L
M:_<M+J?BC7#'U1];\1WVJ:JT;$M#]J$(.R-57\HRBHN)>.<7GD'SY7D%%X'"
M5EK&IBIM4ER:+[53$57NUS1CMJ=]5JAA(T6VZM6U1QT22=G:]W?9=%?LEJ_H
M*OQ5_P""W'[//QH_:*^`?PG\._!/X?:U\1-<T#XNIKNLZ7H9LOM=AH[^#O$N
MG?;WBO+JV\R!;R[MK<^2797GCW*`<U^U5%?H><Y71SK+<5EF(J3I4L72]E.5
M-0YTE.$[QYXR7V+=-'Z')2J.E.,TKN/38_(__@C#\$/C!\`/V4/$/@7XT^!-
M:^'OB>?XR>+/$%AHNNM8F\FT/4/#7@JSMK]5L;N\5(9KW3=0A02O'(QMV?RP
MK+7Z3?%WX1?#[XZ_#_Q%\+_BCX<L?%7@KQ38O8ZMI-\G?*R6U]97"XGL-4TZ
MX2.]TS4K1XKS3[V&&ZM9HYHD<>E9HHP&4X7`97ALH2]OA</AHX7EK+G]I22M
M::>]_5V%4FZE24[)<TG*W17/XE/VI/\`@CG^UI\(/B-K_A7X&>$?%/QL^#VN
MW4.MZ!J^@7&G1WD,-H;]-,TOQKI$U]8I_P`)'H*7MQ;VNIP6TEAJ%I<SWM@U
MG<7E_96?])?_``2B^$OQ(^"'[$'PO^''Q6\)ZCX)\;:1J_Q%O-3\-ZLUJVH6
M,.L^/_$FJZ>UQ]CGN8%^TV%W;74:"7>L<R"5(WXK](**\#).",KR#-<1F>7U
M<5#V]*=%86I4=2A0ISJ4JCIT92O55-.E:,)SFH\SY6M4]JF)G5IQIRC%*+O>
M*MTM:R"OR]_X*`_\$Q?A7^W!IMCXB;4W^'OQIT#2SIF@_$/3[%+RVU33H6EF
MM=!\8Z2LD!U72K>:>5K*[MKBVU;3#+)]FNI+=Y+.7]0J*^ES'+<'FV%G@L?0
MAB,-4^.G.*=G]F<&_@J0UY)K6-WW,(3E3DIP?+);,_E^^$?P_P#^"S'_``3W
MM!X$\&>!?#W[2_P:TN9_[&T&TUB+Q-8:7:/([!?#<4^I>&O'OAZ*0+YK:0MI
M?:+9SR/)!:2,QD;ZFL/^"D__``4+O4.EQ_\`!+7XD'7U0(TLFM^)+#1C*2,,
M)KSP5$BQ;26(.HY4?(6;;NK]VZ*^<PW"N)R^G[#+>)LZPN%3_=X>K'+L=&A'
MI3HU,;@JU6%.*T4>=V[Z*V[KQE9SI0E/K*-X<VVZ5T]E\[L_(CX`?%;_`(*P
M_$#XMZ!J_P`8/V=?@K\*_@?.?LOB+P]?^+#'XR@L)Y8V76M)O=-U;Q=>7>L:
M=&69=*U#2M*TV_#S6D[:=,8;VW_7>BBOH<NP-7`494JN88[,92FY^UQTZ,YP
MYMX4_8T:/+372#YN7H]7?&<E*UH1A;^56OMOZ6/AC]N3]A#X4?MP?#RS\+>-
MVNO#OC'PR;V[^'_Q%T>VAEUGPQ>WD`BN[6X@D,46K^']26.%-4T:>:`2B*.X
MM+JRO88;I/Q@^"?P9_X*S_\`!,Z76_!GPP^'7A?]I_X'7^KS:O'H.D:F+Z"U
MNIMB3:EHVF37^B^,/#&IZA''$VH65M9:]H32H)O*N;A7GD_J&HKR,SX5P&88
MV.:4:^*RS-H+E_M#`3A3JU(:7IXB%2%2E7I.R]RI%I=&KLTA7G&*IR4)TD[J
M$HZ+T:>A^&"_\%.?VY8X?LUQ_P`$K_C*VK@^47AU;Q1_9WV@Y^;S#\.)/W(;
M;EA<,I!)#\8/RA\>?!/_``5V_P""D=E:_#;Q/\%O#_[,GP0GU.UOM6TS7M:C
MTM-3^PW,=S9/XIN)KS4_&?B*/3I<7MEIVF>'-,TF74H;2YN+3S+6.X@_I^S1
M7/B.%\3CJ,L+F7$6;8O!U&O;8:G#`X*->*T]G6J8;#0JSIR^U!3BG^`XUU"2
MG"E!36SE>=MMD]%M_77\XO\`@G]_P3F^&G["OA+5#IFI2>-OBOXPMK2+QS\1
M+RT6R\^VM9!<P^'O#>G[YFTCPW!>`W,D,EQ<7NK72Q7FIW#M;6%M8?H[117T
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M,:4H0FH_#)K57M?3;H?@A_PW)_P6`_Z1O:-_X,]:_P#FKK];OV9/&?QD^('P
M5\(^+_C]\.].^$_Q3UJ/5Y_$'@#2[R6_A\/P0Z[J=GHD<T\US>.+R^T2WT[4
MKNW-S,;.>\DM)&2:&2*/Z!HKV,MRG&8&M.KB,\S',HRIN$:.+CA53BW;WTZ5
M"%2Z2LDJD4^J>ELYU%)65.$._+?7;>]^S^_[RO!?VH/#6N^-/V;?C]X-\+:;
M-J_B;Q;\%OBEX9\/:3`T:3ZGKNN>!];TW2=/A>=HX$FO=0N;>UC,TL46^5=T
MB`YKWG(]12UZU>C#$4:M"I\%6G4I3MI+EJPE!V?1^]==[6,T[24NS_5/]#^4
M;_@CQ^Q+^U7\!/VOO^%@?&+X)>+?`'@^'X6^-M);7M>.E1VC:GJ-SH'V*QC%
MKJ-U,\]PL$[J!"56.&1W9<#/]7-%%>1P[P_A>&\O>78.I6JT77JU^:MR.?-5
MY;KW(Q_E6KO?R-:]>>(GSRT]V,;+RZW\_P``HHHKW3$^5/VW_!GBKXC?LB?M
M$>`O!&BW7B/Q?XN^$GC+0_#FAV+0K>:KJU[I,T=G86QN)(8/.N96$4?FS1H9
M&1"V7%?B]_P1#_9)_:2_9P^*?QQ\0?&[X1^)_ASI/B#X?^'=)T2\U_\`LY4U
M/4;?Q%)>SVUHMG?7<SRPVZ;W)C6-0Z[I%9D1_P"DRBOGL;PYA,=GF6Y]4K8B
MGB<LISI4J<'#V4XS]I?G4XR::=2_N[VUWTVC7G&C.C'13ES-]=DK6^04445]
M"8GP/_P4Z^&7C[XQ_L-?'/X;?##PS?>,/''B6Q\##0_#FF&W6_U(Z1\3O!.N
MWZ6QNIH(=T&EZ;?7;*\JED@8)ND*1O\`F[_P0U_96_:$_9MU/]I&]^.'PN\1
M?#B#Q?9_"JU\.-X@_L]'UB;19?'LNJBTBLKV\<K9#5M/\Z23RE!G"KN*OM_H
M:HKYS$\-X3%9_@.(9U\1#%8##2PU*E!P]C*$O;7<E.,K->V=K)/17;N;*M*-
M&=%:*<N9RZZ6MIY6"O@G]NG]@'X1_MR>"+#1O&KS^&?'?AB.Y;P'\2='MX)M
M8T"2Y3-SIE_:2M%%KOAN_D"2WNC7,\&V1?M=A>6%V7G?[VHSGI7L8[`X7,L+
M5P>-HPKX:O%PJ4YI--/K%OX9QWA-:Q>QG"<J<E.#Y9+9G\M'PO\`V9O^"O?_
M``3BOM1TCX#6WAG]H;X.-J$^HGP=::E:ZGHDYDEEDEO;3PKKNJ>'/%GA?6+L
M'=>P^$[Z[M+N=UENFU.6,O7UGI?_``4H_P""A\2QZ3K'_!+;XC77B';L:?3-
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MNI65PTN^RL--\*ZQ+!!9I')+<W-U,^SYZT?_`(*/_P#!4+PAY=C\3O\`@FQX
MC\23Q*HEO_!.F^.M*BF9<*[A8K/QU9-O`#((KN*,`G`;;D_T)45Y-?A[&RQ-
M?$X7B7.<+*O/VCI-X;$8>F_Y:5*K1_=TTM(P3TO>[TM<*RC%*5*E*VSY>5].
MWH?SZ^(_^"@__!4CXDZ=+HGP;_X)S^)O`>MW8-O!XD\=PZ]J5MIS3?(ES%;Z
M_8>`]'CDAD"NLNIW-S8J0!<02(<-\]_LP?\`!%[XV_$3XT+^T+^W;XFTU)-3
M\7/\0/$/@#2]2M]>\2>-/$,^H'6'@\6ZSI:)X>T72)K\[;_3M$FU.6ZL5;38
M'T=)0\']1V:3</4?G7+/@ZCCL3A\1GF:8_._JM55J&%Q'L*&#A65FI_5L/2B
MI/2-E.4K6TM=WM8J4(2A2A&CS?%*'QZ;6F]59_?U$50@PH`'```P`````.P`
M``':G445]D<H4444`>5?&WX-^!_V@/A=XS^$'Q'TX:KX,\<Z'=:+JULH1;FW
M>4QS6&KZ;.Z2?9-7T34(+;5=(NPC?9=2M+:XV2&(+7\2FIV'[1O_``1]_;+2
MXME>\M]/FG;3KJYBN+/PA\:?A->WRO+;3$-,J2F&UC-W`KS7_A/Q;81W$*3P
MV5K>7W]X%?*7[6_['_PB_;(^%]U\-OBIICF6#[1>^#_&6F)%'XH\#:^\6R+5
M]"O&C<^6Y$<>IZ7<>;8:M:@0WD+216]Q;_$\7<+SSFGAL?EU;ZGG>63]K@<3
M'W?:-<O[BK)._++E]V5GRW?NV9U86O&C.4:BO2JQY)I>NC\[79:_9._:X^$/
M[87PNL/B9\*=9BE'EVUOXI\)7L\*^*/!&O21;Y]$\0V*L7A=2LC6%_&K6&K6
MBB[L9G0R)%]1U_"=\5_@%^VW_P`$E/C+#X^\*ZSK6F^'S>&S\._%OPI:7-Y\
M/O'.DM,)HO#_`(TTBX^TZ?:75U'!`+[PGXE1BUW&UQH-_?FVM=37]K?V3O\`
M@O/\$?B'9:9X8_:;T.X^#7C1EBMY_&6CVNH:_P##36+DA(Q>&.TCO/$OA8W4
MS`"UN[/6-/M@=\^N10CY/-R3C[#N7]E<34Y9-G.'E[*H\4G2PF(<4KU57<52
MI7T?+*5GS>[)V=M*V":3J8=QJTGK%0=W%:?%UUNNG?Y_T"45YO\`#CXO_"WX
MNZ2NN?##XB^"?B#I+I'*+_P=XFT?Q##&DJAD%R-,NKA[27!&Z&Y6*9#P\:GB
MO1\CU%?HE*K3K0C4I5(5825U.G)3B_1IM'#KV%HJ.6:*"-Y9I(X8HT:2225U
MCCC102SN[D*B*`2S,0``23BO@O\`:!_X*7_L;_LWV-]_PFGQC\-^(/$EH)5B
M\#?#N\M_'/BR>YCW?Z)-:Z)--I^B3$H_S>)-1T:`;''F^8!&V&+Q^#P%-UL;
MBL/A:*OS5*]:%)*W92:<O.UVBX4YU)*,(N3?9>G^?ZGWN2`"20`.23P`/4D\
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MW.K_`.")_P#P3IOOAU86_P"UW\:=$DL/&OB/29(/@UX7U.TV7WA?POK-J4O?
M'&H03`O::YXGTZ8V>AP%4EL/#=U=7,YE.O+#9?T=U%%$L*A$`"J`J@``*H)V
MJ`.`%!PH`Z`9R<FI:_0,AR3"</9;1RW!K]W3O.I4<;3KUYV]K6GJ_>FTM+NR
M5KO<XJM65:;G+KI%?RQ6T?E\O0*_._\`;^_;AU;]B[3?@O)H?P\T?Q_J7QB\
M>S>!H%\0>+Y/!FCZ`Z6]C(FJ:EJL6B:V%LEEOXOMD\D,:6=I'-<YE9!"_P"B
M%?EK_P`%-_V,?B=^V%I7P"B^&LWPYDE^$WQ*NO&>OZ'\2[[6+'0?$NE/;:<H
MT60Z3H>O--!?267V;4(;FU6)K">;8SR;8GCB*>90RG$SRE2ECX^Q]A&"@Y2O
MB*/M+<\9+6ESQVT4F]TAT?9^TC[6_L_M6W,#XU_M_?&?]G?P3>^/?B)\.?V5
M/$&F:7LEN?#?P]_:]^U>.=3A:XAA,?AGPWXF^$FAMXBU%5EWKIFGW,MW.(Y#
M%&0@W?H5\!_BROQR^$G@7XK)X.\5^`%\<:!:Z]'X1\;V*:=XET>.Z>=(XM0M
M8Y95$=RD`OM/N-T9O-+NK&]:WMS<>0GYA?$W]C3XR_$;P7K_`(3TW]C_`/X)
MS^`M5UG2KS3]-\;6LWBG4]7\+W-RJQIK>B0Z1\&_"U^NL::1]KTN>#7+#[+J
M$5K=%I8X7MY_M[]B+]GKQ[^S%\"='^%/Q&^,.O\`QL\1V&IZCJC>)M<2[6'2
M+345M?)\)^'SJ5WJ&J-X>T=[>:2Q;4;V><R7MR8H[*S^RV%KYF55,[_M.4,1
M#$U,MJ8-252<*-.-+$1:L^=PH5ZKK)O2E1J*GR+GY5)<UU(T^7FA)W3U3](K
MNW?OJ?7U<EX[\3_\(9X+\6^+19_V@?#'AC7O$0L?-\D7IT32;O5/LAF$<IA^
MT"U\H2B*7R]^_P`M@,5UM<5\1O#UWXM\`^-O"MA)!#>^)_"/B3P]:3W)D%M;
MW.L:->Z?;S7!B5Y/(CFN4:?RTDD$08QQN1BOJJZJNE55'2K[*HJ7;VG+[F^G
MQ'.O/8^9?V#?VK[K]LW]GO1_C?>^"X/`5QJ?B+Q/H$GAZWUJ37XHCX=U$V(N
M5U&73M+=ENEQ)Y1M?W1)`=QS7V?7P+_P3;_9@\=_LA_LPZ%\%_B-JOAO6/$^
MG>*?%^OW-[X4N-2N]&^S^(-5:ZM((;C5=,TB\DFA@5/M&^QB1969$R%W'[ZK
M@R5XUY5@'F,91QSPE%XN,DE)5VGSMI72;=M%_P`!:57!U)>R34+^[>^UO,*_
M-"?]O_6OB?\`'WXA_LY_LH_"&W^+GB?X02M9_%?X@^,O'"_#SX8>#=7BU*?2
M+C18KVR\/^+O$GB/4;?5+34-/FCT[084^UZ7J8MWN;:RFN5_2^OR3T3]AGXO
M_LU?M,?%S]HK]DCQ/X`UG0_CS=W&K?$_X*_%]]>T738]?GU:^\1'6/!_CSPQ
MIGB"^TV0:QJNKSV^G:GX:O[2QBU2YM`UU$NGBPY\ZEFD99?]057ZM]:?]IRP
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M/]JX?M9+^QM_PS?\$S\4F\$GQ_\`VN/CSXM_X0A=!^PF[!;4_P#A3G]N?;MP
M$'V5?#Q3S<-]H$&Z6/\`2;X2ZQ\:M7TG5)/C;X-^'G@K7(=16/2+/X=>.=>\
M=Z;>:5]FC+7=_?>(/`_@:>SO#>"XB2R@LKR/[.D<SW2NYA7XL;]D#XBG_@II
M'^V:-9\*?\*U7X*M\/3HINM47Q=_;K6;V9E^Q?V4=+.FJA%R;C^U_.Q^Z^R[
MUW5^E]?/Y)0S+GQ\LPQ.*:I9CB*6#IU%AXPJY?#D^K56J=&+GS>_:HVI22VC
M;72HX>[R-OW4YWZ3?Q+6^VFO7L%>8?&GXA_\*A^#_P`4OBJ=+.M_\*T^''CC
MQ^=%%U]B.K_\(;X7U/Q$=,6\$%T;1K]=--HMR+:X\AI1*8)0A4^GUX[^T!X#
MU7XI_`GXS_##0KBRL]:^(WPG^(W@/2+S4WGCTZSU3Q?X,UC0-/NM0>VAN+A+
M*WO=1AEO&@@FG6V60PPRR!(V]S%^U6%Q#HK]\J%=T?\`KZJ4W#\2(ZRBNC:N
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M0TGPD^A?$KP!\)OARNA26>F>$/#?P<\0ZSKGA:U\-VUC`D,/DZQX-\&)H\MG
M<"6VM]/T^QN+,6<<$BR02,]NGS?#U;-90PL<V6.CBOJK==5J,_8^V3CS-SIT
MEAH/:UJTN;HE9WUK*FI_NG=?ITU]-?\`,]SI"0H+,0``22>``.I)I:BG@CN8
MI(9E#Q2QO%+&P!62.0;9$8$$%73*-QG:QP0>:^L,3\R?!W_!0?7/VD/B%X[\
M`?L8_!NV^+VD?#.]@TOQK\8_'GCF/X;_``KLM3NYK^*UL_#\ECX=\8^*O%AN
MAIE[+!<:?H-K;M;PI>>:;&[L;NY^E/!/BG]KQ_&&E:=\1_A-\"K3P3>B8ZIX
MH\$_&+QG?ZUHX2%WA6+PQKOPETR/5Y)I0D2HNMZ>BQL\TTD1C2.;XJ^!_P"P
M_P#M`?L.>+?B,W[)'BCX6>.O@S\2O$/_``E-W\(?C8WB?PUK?A/5DMVM%7PQ
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M,_9,_;6^'?[2'P`\`?&3Q!K/@/X;ZSXPM=:?4O!-YX^T2ZNM!NM'\2ZSX?:W
MFGO6TFZ;[7'I46IP^?IUK)]FOX/W;KMEE]<_:A^&>N?&C]G7XW_"/PU=Z?8^
M(/B5\+/''@?1KW5WN(M+M=5\1^'K_2K&:_DM+>ZN8[-+FZC:YDAMIY(X5=EB
M=L*?EG]C/]@/X:?!3]F[X:?#+XR?"CX(>.OB3X9L=<3Q5XJC\"Z#XB_M>]U7
MQ9K^N6T@UGQ#X<MM7O\`[)I>I6&G&:\AC<-9M#&@@BCS\WB*F<K.Z,,)&G+*
MWEE1U)5W.%'Z[];A"%JD*=1JKR2ERP<5S*/Q::;14/92<OC<ERVW26^G7FNO
M2W2Y>\$_M[Z5X]_;R\5?L<>'/#.@ZQH/AOX6P_$!/BEHOC&VU>&]U`VGAR]G
MT--)L;&6S06\7B".*2;^VFN$GMV+6@1OE_1.ORI^&?[!.K_"O_@HYXS_`&J_
M!]A\-?"7P6U[X/1^"-,\$^$[&31-7M/$4EKX5M+R]?0=.T2ST"&UN'T&YNIK
MN'4&N9WEB$MOYA+']5JZLDGFDJ6-_M6*C6CF.*C0Y7>#P:Y/J[IRLG*G;FY9
M2C%O6\5853V?[OV:_P"74.;SG9MOROIH%%%%>T9!1110!X/^TQ\89OV??@'\
M5OC3!H">)YOAKX,UCQ7'H$M^=+CU5]-MQ*MF^H"UO6M%E;`:86LQ49VH6P#D
M_LF_'6;]IC]G;X6_'2?PW'X1G^(V@3ZS+X;BU)M832G@U?4](:!-2:ST][I7
M;3S,KM9P$"3RRN4)*?M<?";7_CM^S/\`&KX.^%;S3-/\1?$7X?:[X7T6\UJ2
MZATFWU+4;4I;2:A-9VE]=Q6OF!5DDM[.Y=`VY87P16'^Q/\`!7Q-^SI^RQ\'
M?@EXQOM'U/Q/\/?#=QI&LW^@37=SH\]U<:YJVJYL)KZSL+N2*.*_CB+SV=NS
M.C$1JI6O%4LP_P!8%%0G_97]E2ES\J]G]>CC865[WYO9MNUK6UZ::J,?8\U_
M>Y^1*VMN5._WZ>OR/JNBBBO:,C\/?#/_``67T>W^,WQ2\(_%GX'ZUX&^"WPV
M^,>O_!?4_CMHNN7'BS1_#GB>QUW6M)\.3>.]%M]"M;O0=+\31:%?21:C;W%X
MEE=0RVHAO%M[B:+ZV_;#_;OT[]F71_V<?$/A7PII/Q6\/_M`?$W0_!%CK.G>
M+(K/3;/1-:CLYH/$.D7]CINM6NM?:+:\2>R19;:TEC1F>\4$8\S_`&/?V"_$
M7PC\6?MT?\+PC^'?C[X=?M3_`!4G\8:/X9MUO=;@?PY=Z[\0-3N+#Q7INLZ+
M8VD-VUMXKTM$BL9]3BCN;*6>*[C:.W9OD?XN_P#!(;XOP>,/AMX9^`'QATI?
MV8?"/QG\,?&.R^$OQ3OM>O=5^&.K:7?2-K>G_#?7;;2]9FO]`U?3[FXDAT35
M9M.6#44CNKB[O+M3J4GYU[;C.CE523I5,7BL5BW3I)K#4,3@(QS&-*$I17+&
MOAL1@U[3VSE&I251_NY))OM7U5U%[K4(J\EJ^>Z[KX;/UO?I8_H0HHHK]%5[
M*^_4XC\_OVA/V^?"7PA^,W@S]F/X=>`_$/QQ_:3\>0QW6D?#;PYJFE^'-+T3
M3I;"_P!635?&OC'5_-L=`L_['TS4=9*6]CJMZFEVANI[:!;FS-SU1\9?M[QV
M\.H?\*)_9JN"YB:;P_'\?_'D6IV\4A`>/^UY/@D^FSW$'60K`L4F&\IFXKQ3
M]H+]@SQCK'[4?AK]MG]FSXC:#X%^/6CZ*GASQ'X<^(.@7GB'X;>/]$31)?#A
M@U)M*NK37?#M^^A/!ITVI::]Z98=+TIX+:UO+>YNKWV^V\2?M[2VHL;CX0?L
MN66HA"C>(/\`A=WQ)O-)\Y0H^TKX;3X,6VH&%\NRVS>(%=541M>G<'KY*%3-
M'C,?',98VE2ABG'+EE^&C5P[P.GLW4JRPV)J2Q._MU.48KW>1O7EZ?<Y82I\
MEW%.:J*SC/K&/=+>^[OMH?8>E7%_<Z?92ZK:6UAJ;V=K)J-E97LNHV=I?20J
MUW:VM_-9:;+>V]O.9(H;N2PLGN8U65[2W9C"FA63H;:LVD::=?CL(M<.GV1U
MF/26N9-*35?LT8U!=,DNXX;N2P%V)?LCW$4<[0&,RHLFX5K5]8G=)]TG^'R.
M8****8!1110!S_BCPMX>\::)J/AKQ7HNE>(_#NL6DUAJVAZYI]IJNDZG97"E
M)[6^TZ_@N;.Z@D7`:.>%U.!QZ_AU^TO_`,$&?V<?B?=:AXC^!?B37?@+XBOF
MEN'T.W@;Q=\.7NB6D/V;0;Z\L];T$3RN?ETCQ`-+M(QBVT3"^3)^\M%>-FN0
M93G5+V.9X*CB8QCR0FXJ-:$=-(5E>4=M;67D:4ZU2C+FIR<>ZZ/U1_%-XS_X
M(E?\%!OA+JSZC\,HO"GQ`^RR/-8ZQ\-_B)%X7U=`&58Y&M?%\G@NXMKMD"N5
MMM0OUC`VI+*\88<S'^S]_P`%K?#RC3+2S_;%MXH,*L6E_%+Q/=V2*`%40SZ=
MXUN+)QP3^YD)!/SD_+C^W^BOCI^&.4Q:6$S7/,#3_P"?5#&IPZ6TJ4YVMY6N
MG9WL=*QM3K"G+U@OT/X>)_V`?^"NWQO\NR\:^$_C1K5A*P\Z;XL_&*PBL8U8
M@AIM/\3>.)KYL?-S%IUU*NQ=T;!]I^N/@C_P;U_%;5KNTU+]H+XQ^%O!FEF1
M9KOP_P##6UO?&'B.X0LKFV?6]8M-#T32K@_O,W-O8^)X]SDB*7/F+_6?15X7
MPPX?IU%5QM;,<TDMX8W$1=&=K?%"E3ISZ;1J16KT#Z]57P*%/I[BM?;?^NK/
MBO\`9=_X)_\`[,'[(=E&WPD\`6X\5-;_`&;4/B-XHD3Q#X^U)'7;.KZY=PJF
ME6MSRUQIGAVTT;2Y7+2/9-))([?:E%%?>X/!83`4(8;!8>EAL/#2%*C!0A'T
M2.24I3DY2;E)[R>K?S"BBBNHD****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
7`****`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
